Who are Dinutuximab. Immunotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ch14.18, DANYELZA, DANYELZA, Ch14.18/CHO, monoclonal antibodies GD2, monoclonal antibody Ch14.18.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dinutuximab-immunotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Dinutuximab. Immunotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dinutuximab. Immunotherapy (Dinutuximab. Immunotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Oncology.

phase 2 Monoclonal antibody GD2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Dinutuximab. Immunotherapy (Dinutuximab. Immunotherapy) — Fundació Sant Joan de Déu. Monoclonal antibody targeting GD2

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dinutuximab. Immunotherapy TARGET	Dinutuximab. Immunotherapy	Fundació Sant Joan de Déu	phase 2	Monoclonal antibody	GD2
Ch14.18	DINUTUXIMAB	United Therap	marketed	Glycolipid Disialoganglioside-directed Antibody [EPC]	GD2	2015-01-01
DANYELZA	NAXITAMAB-GQGK	Y-MABS THERAPEUTICS INC	marketed	Glycolipid Disialoganglioside-directed Antibody [EPC]	GD2
DANYELZA	DANYELZA	Memorial Sloan Kettering Cancer Center	marketed	GD2-targeting monoclonal antibody	GD2 (disialoganglioside)
Ch14.18/CHO	Ch14.18/CHO	University Hospital Southampton NHS Foundation Trust	phase 3	Monoclonal antibody (GD2-targeting immunotherapy)	GD2 (disialoganglioside)
monoclonal antibodies GD2	monoclonal antibodies GD2	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	phase 3	Monoclonal antibody	GD2
monoclonal antibody Ch14.18	monoclonal antibody Ch14.18	National Cancer Institute (NCI)	phase 3	Monoclonal antibody	GD2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dinutuximab. Immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/dinutuximab-immunotherapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing